Cargando…

Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy

PURPOSE: To evaluate the efficacy, safety and tolerability of changing to travoprost BAK-free from prior prostaglandin therapy in patients with primary open-angle glaucoma or ocular hypertension. DESIGN: Prospective, multi-center, historical control study. METHODS: Patients treated with latanoprost...

Descripción completa

Detalles Bibliográficos
Autores principales:	Henry, J Charles, Peace, James H, Stewart, Jeanette A, Stewart, William C
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2008
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694010/ https://www.ncbi.nlm.nih.gov/pubmed/19668762

Ejemplares similares

Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
por: Miyashiro, Michael J, et al.
Publicado: (2010)

Efficacy and patient tolerability of travoprost BAK-free solution in patients with open-angle glaucoma and ocular hypertension
por: Mirza, Sophia K, et al.
Publicado: (2010)

A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension
por: Godfrey, David A, et al.
Publicado: (2009)

Ocular Surface Disease with BAK preserved Travoprost and Polyquaternium 1(Polyquad) preserved Travoprost
por: Kumar, Suresh, et al.
Publicado: (2019)

First experience with BAK-free travoprost 0.004% in topical glaucoma medication
por: Gado, Ahmed Salah, et al.
Publicado: (2012)

Safety and efficacy of changing to the travoprost/timolol maleate fixed combination (DuoTrav) from prior mono- or adjunctive therapy
por: Pfeiffer, Norbert, et al.
Publicado: (2010)

Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost
por: Katz, Gregory, et al.
Publicado: (2010)

Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma
por: Inoue, Kenji, et al.
Publicado: (2012)

Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure
por: Quaranta, Luciano, et al.
Publicado: (2015)

Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%
por: Dubiner, Harvey B, et al.
Publicado: (2012)

Sustainability of Intraocular Pressure Reduction of Travoprost Ophthalmic Solution in Subjects with Normal Tension Glaucoma
por: Naito, Tomoko, et al.
Publicado: (2016)

A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension
por: Rhee, Douglas J, et al.
Publicado: (2008)

Efficacy and safety of travoprost 0.004%/timolol 0.5% fixed combination as transition therapy in patients previously on prostaglandin analog monotherapy
por: Costa, Vital Paulino, et al.
Publicado: (2012)

Efficacy of travoprost for the treatment of patients with glaucoma
por: Zhang, Xiu-Li, et al.
Publicado: (2019)

Effectiveness of ophthalmic solution preservatives: a comparison of latanoprost with 0.02% benzalkonium chloride and travoprost with the sofZia preservative system
por: Ryan, Gerard, et al.
Publicado: (2011)

Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost
por: García-Feijoo, Julian, et al.
Publicado: (2016)

Efficacy of the travoprost/timolol fixed combination versus the concomitant use of travoprost 0.004% and timolol 0.1% gel formulation
por: Kozobolis, Vassilios, et al.
Publicado: (2018)

Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations
por: Suzuki, Emilio Rintaro, et al.
Publicado: (2010)

Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations
por: Fukuda, Masamichi, et al.
Publicado: (2013)

Efficacy and safety of fixed-combination bimatoprost/timolol ophthalmic solution
por: Moon, Suk Bae, et al.
Publicado: (2017)

Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions
por: Campbell, Joanna H, et al.
Publicado: (2014)

Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension
por: Teus, Miguel A, et al.
Publicado: (2009)

Efficacy and tolerability of brinzolamide/brimonidine suspension and prostaglandin analogs in patients previously treated with dorzolamide/timolol solution and prostaglandin analogs
por: Lo, Jonathan S, et al.
Publicado: (2016)

Travoprost Induced Granulomatous Anterior Uveitis
por: Chiam, Patrick
Publicado: (2011)

Pooled results of two randomized clinical trials comparing the efficacy and safety of travoprost 0.004%/timolol 0.5% in fixed combination versus concomitant travoprost 0.004% and timolol 0.5%
por: Gross, Ronald L, et al.
Publicado: (2007)

Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort
por: Gonzalez, Agustin L
Publicado: (2018)

A unified strategy to prostaglandins: chemoenzymatic total synthesis of cloprostenol, bimatoprost, PGF(2α), fluprostenol, and travoprost guided by biocatalytic retrosynthesis
por: Zhu, Kejie, et al.
Publicado: (2021)

Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from β-blockers and prostaglandin analogs
por: Inoue, Kenji, et al.
Publicado: (2012)

Efficacy and tolerability of a large scale change in regimen from latanoprost to travoprost in glaucoma patients at the Manhattan Veterans Administration Hospital
por: Farris, Edmund P
Publicado: (2008)

Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomised, masked-evaluator, multicentre study
por: Kammer, J A, et al.
Publicado: (2010)

Gatifloxacin Ophthalmic Solution for Treatment of Bacterial Conjunctivitis: Safety, Efficacy and Patient Perspective
por: Schultz, Clyde
Publicado: (2012)

Safety and efficacy of fixed-combination travoprost/timolol in patients with open-angle glaucoma or ocular hypertension not controlled with timolol monotherapy
por: Jordão, Marcelo Lopes da Silva, et al.
Publicado: (2014)

Efficacy And Safety Of Travoprost Versus Timolol To Treat Early-Onset Ocular Hypertension Secondary To Vitrectomy: A Randomized Trial
por: Fang, Yuan, et al.
Publicado: (2019)

Safety and Tolerability of Bilastine 0.6% Ophthalmic Solution: An 8-Weeks Phase III Study
por: Kuna, Piotr, et al.
Publicado: (2023)

A Randomised Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Palovarotene Ophthalmic Solution
por: Foster, William J., et al.
Publicado: (2022)

Fixed combination of travoprost and timolol maleate reduces intraocular pressure in Japanese patients with primary open-angle glaucoma or ocular hypertension: analysis by prostaglandin analogue
por: Nakano, Tadashi, et al.
Publicado: (2016)

BAK-up: the receptor kinase BAK-TO-LIFE 2 enhances immunity when BAK1 is lacking
por: Fallahzadeh-Mamaghami, Vahid, et al.
Publicado: (2023)

Travoprost in the management of open-angle glaucoma and ocular hypertension
por: Denis, Philippe, et al.
Publicado: (2007)

The diurnal and nocturnal effects of travoprost in normal-tension glaucoma
por: Seibold, Leonard K, et al.
Publicado: (2014)

Hypertrichosis and Hyperpigmentation in the Periocular Area Associated with Travoprost Treatment
por: Lee, Hae-Eul, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ve3hectkojr1k2ojr14h3nf8f4